Research and Markets: In 2008, the Scale of the Chinese Diagnostic Reagent Market Was About 600 Million USD Says 2009 Research Report on the Chinese Diagnostic Reagent Industry

DUBLIN--(Business Wire)--
Research and
Markets(http://www.researchandmarkets.com/research/0d7fd9/research_report_of)
has announced the addition of the "Research Report of Chinese Diagnostic Reagent
Industry, 2009" report to their offering.

The development of Chinese laboratory medicine fell far behind the world's
advanced level for a long time. In the 1970s, China still continued to use the
methods in the 1950s, namely, the various necessary diagnostics reagents were
self-prepared by the technicians. In the 1970s, China began to introduce some
foreign advanced equipments and technologies. Since the 1980s, Chinese clinical
diagnostic reagent industry had quickly step into the industrialization process
with the introduction of the foreign capitals.

In 2008, the scale of the Chinese diagnostic reagent market was about 600
million USD with the growth speed of 15 to 20 percent in recent years.

Generally speaking, the widely clinically applied and vast market technologies
of Chinese major enterprises have achieved the international level of the same
period, including the immunodiagnostics of hepatitis, sexually transmitted
diseases and fertility test and the enzymes, Lipids, liver function, blood sugar
and urinalysis series in the clinical biochemical. The PCR technology for the
genetic test had reached to the international advanced level; the technologies
of DNA Chips and tumor series are running to catch up the international level.

Due to the market and policy factors and the backward application technologies
of domestic electromechanical integration, some projects in the microbiology are
developed slowly in low technologies.

The biggest perplex of Chinese diagnostic reagent industry is the repeated
appearance of the same kind products in inferior quality, affecting the healthy
development of the whole industry. These projects are derived from the domestic
researches or imported abroad by various channels but without real creativity.

At present, there are hundreds of diagnostic technology enterprises in various
sizes, but the scale is limited and some are even in the laboratory phase. The
diagnostic enterprises, as a new biological hi-tech enterprises, start late in
China. Compared with the multinational enterprises, the domestic enterprises are
in small scales, few varieties and in disparate development. Many enterprises
invest huge research capitals in the former period, leading to the meaning
losses because of the long exploitation period and fast market changes.

The mergers in Chinese diagnostic reagent industry have been on, in which the
small enterprises will be replaced and the large enterprises will be grown in
strength.

From the present situation, the diagnostic reagent industry and the equipment
industry are under developed in local Chinese enterprises, forming the patterns
that the equipments can't match with the reagents. Compared with foreign
companies, the biggest disadvantage of the local enterprises is the brand,
because the foreign funded enterprises have long histories, the consumers prefer
to choose the foreign brands. The advantages of the local enterprises lie in the
familiarity with the local market demands and price competitiveness. At present,
these enterprises enable to cover or solve the problems in the second class
hospitals. Although there is no problem in covering the third class hospitals,
the make-up in the automation systems, data processing and the general
industrialization level are behind the foreign technologies.

Although in its beginning phase, the high profit return attracts many investors
to enter Chinese diagnostic reagent industry. On 5th June, 2007, the first
multinational capital import was succeeded in the field of Chinese diagnostic
reagents. Beijing Chemclin Biotech Co., Ltd, provider of the diagnostic reagents
and equipments, announced the first round obtainment of 5-million-USD venture
investments, dominated by WI Harper Group and Siemens Venture Capital and
participated by SB China Venture Capital.

The profit return of the diagnostic reagents is very high. The overall
investments in a new diagnostic reagent can be recovered after the public in 2
to 3 years, especially the enterprises with new products or patented products.
Once the products exploitation is successful, the technologies will be
monopolized with the profit return exceeding 10 folds or more.

Chinese medical reforms had been started since the latter half of 2008. The key
point of the medical reforms was to develop towards the medium and low market,
request the diagnostics and prevention to be more accurate so as to cut down the
costs and improve the medical treatment efficiency. This was a big market and
only the products with low costs could meet the demands. In the Major Recent
Implementation Plans of Chinese Pharmaceuticals and Hygienic System Reform (2009
to 2010), the intensification in the basic public hygiene services will drive
the sharp sales growth of the diagnostic reagent products, pointing out the
control and prevention and national immunity plans against the big epidemics,
such as T.B. and AIDS. It is predicted that the basic public hygiene services
will propel the sales growth of Chinese common diagnostic preparation.

From the medically clinical experiences in the developed countries, the
diagnostic costs account for 20 to 30 percent of the whole medical costs, but
which is less than 10% in China. Therefore, great market space has not been
exploited so far.

More of the following information can be obtained in this report:

* Present Development Situation of Chinese Diagnostic Reagent Industry
* Development Situations of the Sub-sectors in Chinese Diagnostic Reagent
Industry
* Factors affecting the Development of Chinese Diagnostic Reagent Industry
* Major Local Enterprises and Their Operations of Chinese Diagnostic Reagent
Industry
* Distributions of Foreign Funded Enterprises in Chinese Diagnostic Reagent
Market
* Influences of International Financial Crisis on the Sun-sectors of Chinese
Diagnostic Reagent Industry
* Development Trends of Chinese Diagnostic Reagent Industry
* Investment Opportunities of Chinese Diagnostic Reagent Industry

For more information visit
http://www.researchandmarkets.com/research/0d7fd9/research_report_of

Laura Wood
Senior Manager
press@researchandmarkets.com
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716

Copyright Business Wire 2009